Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 11:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 71 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Oral Antihyperglycemic Medication Clear all
Completed Phase 3 Interventional Results available

Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes

NCT00116831
View directory record Official record
Conditions
Atherosclerosis
Interventions
Glipizide, rosiglitazone maleate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 80 Years
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
39
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Sep 29, 2026, 11:38 AM EDT
Completed No phase listed Observational Results available

Ascertainment of EMR-based Clinical Covariates Among Patients Receiving Oral and Non-insulin Injected Hypoglycemic Therapy

NCT02140645
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
linagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
166,613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Sep 29, 2026, 11:38 AM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs

NCT03078478
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Insulin degludec, Insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
156
States / cities
Anniston, Alabama • Birmingham, Alabama • Chandler, Arizona + 135 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Sep 29, 2026, 11:38 AM EDT
Completed Phase 3 Interventional Results available

Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)

NCT00308139
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide, long acting release, exenatide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
16 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
24
States / cities
Encino, California • La Jolla, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Sep 29, 2026, 11:38 AM EDT
Completed Phase 3 Interventional Results available

A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes

NCT03214380
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec, Metformin, SGLT2 inhibitor
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
933 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
32
States / cities
Fresno, California • La Mesa, California • Lancaster, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Sep 29, 2026, 11:38 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment

NCT01620489
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
53
States / cities
Concord, California • La Jolla, California • Los Angeles, California + 47 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Sep 29, 2026, 11:38 AM EDT
Completed Phase 4 Interventional Results available

Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial

NCT03596450
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Semaglutide, Standard of care
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
121
States / cities
Buena Park, California • Fullerton, California • Garden Grove, California + 104 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 29, 2026, 11:38 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Antidiabetic Medications on the Postprandial State in Prediabetes

NCT02104739
View directory record Official record
Conditions
Prediabetes, Obesity
Interventions
Exenatide, Saxagliptin, Exenatide extended-release (ER), Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
30 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Sep 29, 2026, 11:38 AM EDT
Completed Phase 3 Interventional Results available

A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus

NCT02302716
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2963016, LANTUS®, Oral Antihyperglycemic Medication
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Miami, Florida • New Port Richey, Florida • Smyrna, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Sep 29, 2026, 11:38 AM EDT
Completed Phase 3 Interventional Results available

A Study in Patients With Type 2 Diabetes Mellitus

NCT01435616
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Glargine, LY2605541
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
66
States / cities
Anniston, Alabama • Mobile, Alabama • Chandler, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2018 · Synced Sep 29, 2026, 11:38 AM EDT
Completed Phase 3 Interventional Results available

A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus

NCT02597049
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Dulaglutide, Placebo, SGLT2 inhibitor, Metformin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
13
States / cities
Encino, California • Huntington Park, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Sep 29, 2026, 11:38 AM EDT
Completed Phase 4 Interventional Results available

Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly

NCT02060383
View directory record Official record
Conditions
Cushing's Disease, Acromegaly
Interventions
Pasireotide s.c., Sitagliptin, Liraglutide, Insulin, Pasireotide LAR, Metformin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
15
States / cities
Multiple Locations, California • Torrance, California • Ventura, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Sep 29, 2026, 11:38 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF)

NCT03608163
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Hypoglycemia, Hypoglycemia Unawareness
Interventions
Naloxone, Diazoxide, Placebo (for Naloxone), Placebo (for Diazoxide)
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
21 Years to 55 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 29, 2026, 11:38 AM EDT
Completed Phase 3 Interventional Results available

Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes

NCT00859898
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Dapagliflozin, Metformin XR, dapagliflozin matching Placebo, metformin HCl Modified Release matching Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
1,093 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
64
States / cities
Ozark, Alabama • Tempe, Arizona • Concord, California + 53 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Sep 29, 2026, 11:38 AM EDT
Completed Phase 4 Interventional

24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine

NCT00551538
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Lispro mix 75/25, Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 12, 2010 · Synced Sep 29, 2026, 11:38 AM EDT
Enrolling by invitation Early Phase 1 Interventional

Truway Diagnostic Tools in Primary Care

NCT07209527
View directory record Official record
Conditions
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, Hypertension, Cardiovascular Disease Acute, Hyperlipidemia, Chronic Kidney Disease (CKD), Stages 3-4 Exercise Tolerance / Functional Capacity Vascular Health / Arterial Stiffness Fatigue in CKD, Peripheral Artery Disease, Metabolic Syndrome, Prediabetes
Interventions
Truway Portable Ultrasound Device, Truway Blood Glucose Monitor, Standard Oral Hypoglycemic Agent
Device · Drug
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 29, 2026, 11:38 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Mechanisms of Hypoglycemia Associated Autonomic Dysfunction Question 2

NCT00574639
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Alprazolam, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 29, 2026, 11:38 AM EDT
Withdrawn Not applicable Interventional

Proteus Sustained Behavior Change Study

NCT01503008
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Proteus Sustained Behavior Change system, Regularly prescribed diabetes medicines (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors)
Device · Drug
Lead sponsor
Proteus Digital Health, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Sep 29, 2026, 11:38 AM EDT
Completed Phase 4 Interventional Results available

Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes

NCT02455076
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Exenatide, Glargine, Rapid-acting insulin analogs
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Sep 29, 2026, 11:38 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

NCT00528879
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo, Metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
915 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
28
States / cities
Tempe, Arizona • Encino, California • Fresno, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Sep 29, 2026, 11:38 AM EDT
Completed No phase listed Observational

Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes Taking Twice-Daily Exenatide or Once-Weekly Exenatide

NCT00803920
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
HealthPartners Institute
Other
Eligibility
16 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Sep 29, 2026, 11:38 AM EDT
Completed No phase listed Observational

Carnitine Levels and Carnitine Supplementation in Type I Diabetes

NCT00351234
View directory record Official record
Conditions
Diabetes Mellitus, Type I, Hypoglycemia
Interventions
Carnitine (drug)
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
7 Years to 21 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Sep 29, 2026, 11:38 AM EDT
Completed Phase 3 Interventional Results available

A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus

NCT01582451
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2605541, Insulin glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
33
States / cities
Mesa, Arizona • Phoenix, Arizona • Concord, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2018 · Synced Sep 29, 2026, 11:38 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients

NCT01798706
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Lixisenatide (AVE0010), Placebo, Antidiabetic background therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
70 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
14
States / cities
La Jolla, California • Norwalk, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 29, 2026, 11:38 AM EDT